Protagonist Therapeutics (PTGX) is Initiated by Barclays to Overweight, Price Target at $18

Protagonist Therapeutics (PTGX) was Initiated by Barclays to “Overweight” and the brokerage firm has set the Price Target at $18. Barclays advised their investors in a research report released on Sep 6, 2016.

Many Wall Street Analysts have commented on Protagonist Therapeutics. Protagonist Therapeutics was Initiated by Leerink Partners to “Outperform” on Sep 6, 2016.

Protagonist Therapeutics

Leave a Reply

Protagonist Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Protagonist Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.